NCT01928186 2018-05-15
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
University of Washington
Phase NA Completed
University of Washington
Vanderbilt-Ingram Cancer Center
Abramson Cancer Center at Penn Medicine
UNICANCER
National Taiwan University Hospital